相关临床试验
26
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1984
已完成
12
46.1%
Enrolling By Invitation
1
3.9%
尚未招募
3
11.5%
招募中
9
34.6%
Unknown
1
3.9%
暂无批准数据
- A UK Biobank study of 66,483 adults found longer moderate-to-vigorous physical activity bouts and less fragmented activity were each associated with significantly lower future risk of dementia, depression, and anxiety. - Compared with the highest activity fragmentation, the lowest fragmentation was linked to an 82%, 57%, and 52% lower risk of dementia, depression, and anxiety, respectively. - Neuroimaging in 13,108 participants showed prolonged activity bouts and lower fragmentation correlated with greater hippocampal volume and lower white matter hyperintensity volume. - Among APOE4 carriers, dementia risk progressively decreased as activity fragmentation decreased, suggesting activity patterns may be a modifiable target for genetically predisposed individuals.
- A phase II study of 72 patients demonstrated that the combination of cabozantinib and temozolomide achieved a 79.4% progression-free survival rate at 12 weeks in patients with unresectable or metastatic leiomyosarcoma. - The dual-targeting approach yielded a median progression-free survival of 6.3 months and median overall survival of 19.2 months in the leiomyosarcoma cohort. - Treatment was well-tolerated with manageable toxicity profiles, with the most common grade 3-4 adverse events being platelet count decrease (30%) and neutrophil count decrease (18%). - The combination therapy targets both VEGF and MET pathways simultaneously, representing a novel therapeutic strategy for this rare and aggressive soft tissue sarcoma.
- Global rheumatoid arthritis incidence increased 13.2% from 1990 to 2021, affecting 17.9 million people worldwide by 2021, with significant regional disparities and a shift toward younger age groups. - Despite rising incidence, RA-related mortality dropped by 32.7% over the study period, from 0.09 to 0.06 per 100,000 people, attributed to improved diagnostic capabilities and treatment advances. - Women face disproportionately higher disease burden than men, with mortality rates of 0.08 versus 0.04 per 100,000 people and significantly higher disability-adjusted life years. - AI-driven forecasting models predict continued global RA burden growth through 2040, particularly in low- and middle-income countries, highlighting urgent need for targeted public health interventions.
